Our universal influenza nanovaccine will be effective against more strains of fluRespiratory infections research
Nanovaccines can prevent parasitic diseases such as malaria and filariasisAntimicrobial Resistance research
We're researching tumor-specific targets for cancer diagnostics and nanotherapeuticsCancer research
Nanotechnologies can help optimize aging with improved biosensors and vaccine deliveryAging research
Researching veterinary diseases helps design nanovaccines for similar diseases in humansAnimal health research
Consortium of experts
The Nanovaccine Institute is a consortium of 79 researchers at 24 universities, research institutes, national laboratories, and companies, founded and coordinated by Iowa State University.
Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, antimicrobial resistance, cancer, aging, and animal health. Our vision is that nanovaccines and nanotherapeutics will revolutionize how we prevent and treat disease.
NANOVACCINE INSTITUTE RESEARCHER PROFILE
Dr. Surya Mallapragada, Iowa State University